ERASMUS MC AND INGENUITY TO COLLABORATE ON ADVANCING TECHNOLOGY AND MOLECULAR DIAGNOSTICS
Rotterdam, Netherlands and Mountain View, CA, March 23, 2005 – Ingenuity announced today that the Erasmus MC in Rotterdam has licensed access to the IPA software. Under the terms of the agreement all researchers at the Erasmus MC will have access to the full functionality of the IPA product.
“IPA is the first application to bring the underlying biology of microarray and proteomics experiments to scientists and clinicians in a comprehensive way, said Prof. Dr. Peter J. van der Spek. “Its interface, ease-of-use, and most importantly, its biological insights, make this a required solution for anyone doing gene or protein based research.”
In addition to the expanded licensing agreement of the IPA application, Ingenuity and the Erasmus MC are collaborating on the development of new algorithms, visualizations and practical applications in molecular and clinical diagnostics. Furthermore, Erasmus MC is involved in product development in proteomics around applications developed at Ingenuity.
“We are committed to ensuring broad access to IPA for the academic and government research community and are thrilled to be able to develop strong relationships with leading researchers and institutions, like Prof. Dr. van der Spek and the Erasmus MC,” stated Jake Leschly, President and CEO of Ingenuity. “Prof. Dr. van der Spek and his outstanding team are uniquely positioned to apply advanced pathways analysis to the advancement of clinical understanding and diagnostics and we are very excited about the potential for our collaboration.”
IPA helps researchers gain biological insight and understanding from their experimental datasets. It is deployed with leading research labs around the world and at 15 of the largest 20 pharmaceutical companies where it is being used to make better and faster decisions in all areas of drug discovery and development, from target identification and validation to biomarkers, predictive toxicology, and patient stratification.
The web-delivered application makes use of the Ingenuity Pathways Knowledge Base, the world’s largest curated database consisting of millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases.
About Ingenuity Systems
Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.www.ingenuity.com.